SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 27 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,151,000 | +79.0% | 123,683 | +0.9% | 0.00% | +50.0% |
| Q1 2019 | $643,000 | +18.0% | 122,553 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $545,000 | -46.7% | 122,553 | -3.2% | 0.00% | -33.3% |
| Q3 2018 | $1,023,000 | +15.1% | 126,663 | 0.0% | 0.00% | +50.0% |
| Q2 2018 | $889,000 | -51.3% | 126,663 | -1.2% | 0.00% | -60.0% |
| Q1 2018 | $1,824,000 | +65.4% | 128,198 | +1.8% | 0.01% | +66.7% |
| Q4 2017 | $1,103,000 | -15.8% | 125,887 | +12.5% | 0.00% | -25.0% |
| Q3 2017 | $1,310,000 | -14.1% | 111,923 | +2.5% | 0.00% | -20.0% |
| Q2 2017 | $1,525,000 | +7.3% | 109,168 | +5.4% | 0.01% | +25.0% |
| Q1 2017 | $1,421,000 | +84.1% | 103,540 | -3.8% | 0.00% | +33.3% |
| Q4 2016 | $772,000 | -42.9% | 107,680 | +20.7% | 0.00% | -40.0% |
| Q3 2016 | $1,352,000 | +143.2% | 89,200 | +58.2% | 0.01% | +150.0% |
| Q2 2016 | $556,000 | -28.0% | 56,400 | -2.7% | 0.00% | -33.3% |
| Q1 2016 | $772,000 | – | 57,990 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |